208 related articles for article (PubMed ID: 32799776)
1. Atypical response patterns in metastatic melanoma and renal cell carcinoma patients treated with nivolumab: A single center experience.
Yilmaz M
J Oncol Pharm Pract; 2021 Jul; 27(5):1106-1111. PubMed ID: 32799776
[TBL] [Abstract][Full Text] [Related]
2. Fatal hyperprogression induced by nivolumab in metastatic renal cell carcinoma with sarcomatoid features: a case report.
Dionese M; Pierantoni F; Maruzzo M; Bimbatti D; Deppieri FM; Maran M; Gardiman MP; Basso U
Anticancer Drugs; 2021 Feb; 32(2):222-225. PubMed ID: 32868643
[TBL] [Abstract][Full Text] [Related]
3. Site-specific Response to Nivolumab in Renal Cell Carcinoma.
Negishi T; Furubayashi N; Nakagawa T; Nishiyama N; Kitamura H; Hori Y; Kuroiwa K; Son Y; Seki N; Tomoda T; Okajima E; Nakamura M
Anticancer Res; 2021 Mar; 41(3):1539-1545. PubMed ID: 33788747
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Programmed Cell Death-1 Inhibitor Therapy.
Zheng B; Shin JH; Li H; Chen Y; Guo Y; Wang M
Korean J Radiol; 2021 Mar; 22(3):366-375. PubMed ID: 33289356
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database.
Yekedüz E; Ertürk İ; Tural D; Karadurmuş N; Karakaya S; Hızal M; Arıkan R; Arslan Ç; Taban H; Küçükarda A; Öztaş NŞ; Sever ÖN; Uçar G; Can O; Şendur MA; Demirci U; Kılıçkap S; Çiçin İ; Öksüzoğlu B; Özgüroğlu M; Ürün Y
Future Oncol; 2021 Dec; 17(35):4861-4869. PubMed ID: 34726480
[TBL] [Abstract][Full Text] [Related]
6. A real-world data of Immune checkpoint inhibitors in solid tumors from India.
Noronha V; Abraham G; Patil V; Joshi A; Menon N; Mahajan A; Janu A; Jain S; Talreja VT; Kapoor A; Kumar Singh G; Khaddar S; Gupta K; Rathinasamy N; Srinivas S; Agrawal A; Ventrapati P; Prabhash K
Cancer Med; 2021 Mar; 10(5):1525-1534. PubMed ID: 33591635
[TBL] [Abstract][Full Text] [Related]
7. Long-term response to immuno-oncology after discontinuation for immuno-related pneumonia in metastatic renal carcinoma: a case report.
Stellato M; Foderaro S; Tonini G; Vincenzi B; Santini D
Anticancer Drugs; 2022 Jan; 33(1):105-108. PubMed ID: 34232938
[TBL] [Abstract][Full Text] [Related]
8. Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients.
Derosa L; Routy B; Fidelle M; Iebba V; Alla L; Pasolli E; Segata N; Desnoyer A; Pietrantonio F; Ferrere G; Fahrner JE; Le Chatellier E; Pons N; Galleron N; Roume H; Duong CPM; Mondragón L; Iribarren K; Bonvalet M; Terrisse S; Rauber C; Goubet AG; Daillère R; Lemaitre F; Reni A; Casu B; Alou MT; Alves Costa Silva C; Raoult D; Fizazi K; Escudier B; Kroemer G; Albiges L; Zitvogel L
Eur Urol; 2020 Aug; 78(2):195-206. PubMed ID: 32376136
[TBL] [Abstract][Full Text] [Related]
9. [Initial Clinical Experience of Nivolumab for Metastatic Renal Cell Carcinoma].
Fukunaga A; Yamasaki T; Okuno T; Imai K; Ikeuchi R; Hishiki K; Goto T; Sawada A; Negoro H; Akamatsu S; Saito R; Kobayashi T; Inoue T; Ogawa O
Hinyokika Kiyo; 2018 Oct; 64(10):383-389. PubMed ID: 30543735
[TBL] [Abstract][Full Text] [Related]
10. Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients.
Basak EA; van der Meer JWM; Hurkmans DP; Schreurs MWJ; Oomen-de Hoop E; van der Veldt AAM; Bins S; Joosse A; Koolen SLW; Debets R; Peeters RP; Aerts JGJV; Mathijssen RHJ; Medici M
Thyroid; 2020 Jul; 30(7):966-973. PubMed ID: 32151195
[No Abstract] [Full Text] [Related]
11. Hyperprogression after nivolumab for melanoma: A case report.
Yilmaz M; Akovali B
J Oncol Pharm Pract; 2020 Jan; 26(1):244-251. PubMed ID: 31068087
[TBL] [Abstract][Full Text] [Related]
12. Radiomics can predict tumour response in patients treated with Nivolumab for a metastatic renal cell carcinoma: an artificial intelligence concept.
Khene ZE; Mathieu R; Peyronnet B; Kokorian R; Gasmi A; Khene F; Rioux-Leclercq N; Kammerer-Jacquet SF; Shariat S; Laguerre B; Bensalah K
World J Urol; 2021 Sep; 39(9):3707-3709. PubMed ID: 32632555
[No Abstract] [Full Text] [Related]
13. Assessing the prognostic value of IMDC risk score for nivolumab-treated patients with renal cancer and malignant melanoma.
Beypınar I; Sözel Y; Önder AH
Cancer Biomark; 2023; 38(3):367-377. PubMed ID: 37718781
[TBL] [Abstract][Full Text] [Related]
14. Hyperprogression and hypercalcemia after nivolumab treatment in three cases with renal cell carcinoma.
Caner B; Ertas H; Ocak B; Cubukcu E
J Oncol Pharm Pract; 2022 Oct; 28(7):1645-1649. PubMed ID: 35188841
[TBL] [Abstract][Full Text] [Related]
15. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC
Cancer; 2018 Sep; 124(18):3677-3683. PubMed ID: 30307610
[TBL] [Abstract][Full Text] [Related]
16. Association of Systemic Steroid Treatment and Outcome in Patients Treated with Immune Checkpoint Inhibitors: A Real-World Analysis.
Paderi A; Gambale E; Botteri C; Giorgione R; Lavacchi D; Brugia M; Mazzoni F; Giommoni E; Bormioli S; Amedei A; Pillozzi S; Matucci Cerinic M; Antonuzzo L
Molecules; 2021 Sep; 26(19):. PubMed ID: 34641331
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab-induced Adrenal Insufficiency in Patients With Renal Cell Carcinoma.
Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
J Immunother; 2020 Jan; 43(1):38-42. PubMed ID: 31567704
[TBL] [Abstract][Full Text] [Related]
18. Magnetic resonance imaging criteria of immune checkpoint inhibitor-induced hypophysitis.
Nada A; Bhat R; Cousins J
Curr Probl Cancer; 2021 Feb; 45(1):100644. PubMed ID: 32888700
[TBL] [Abstract][Full Text] [Related]
19. Pseudoprogression and Mixed Responses in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab: A Retrospective Analysis.
Haaker L; Baldewijns M; De Wever L; Albersen M; Debruyne PR; Wynendaele W; De Meerleer G; Beuselinck B
Clin Genitourin Cancer; 2023 Aug; 21(4):442-451. PubMed ID: 36997468
[TBL] [Abstract][Full Text] [Related]
20. An evaluation of nivolumab for the treatment of metastatic renal cell carcinoma.
Zarrabi K; Wu S
Expert Opin Biol Ther; 2018 Jun; 18(6):695-705. PubMed ID: 29782188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
